Enhanced Chemical Method for Bispecific Antibody Production: Leveraging Site-Specific Conjugation and Stable Crosslinker Technology
- 1 May 2026
- book chapter
- Published by Springer Nature
- Vol. 2997, 107-118
Abstract
Bispecific antibodies (BisAbs) represent a major breakthrough in biotherapeutics by combining the functionalities of two different antibodies to unlock their potential for a wide range of applications. Conventional BisAb production has relied on labor-intensive and complex genetic engineering methods. This chapter introduces a cutting-edge protocol that circumvents the need for genetic modifications by using chemical conjugation strategies. We present a streamlined, fully chemical methodology for generating BisAbs that leverages the precision of the AJICAP second-generation technology for accurate site-specific conjugation. In addition, this chapter explores the application of haloketone chemistry as an improved and more effective replacement for traditional maleimide-based crosslinking techniques for the fusion of two antibody-related proteins. The analytical performance and results of the newly developed BisAb were thoroughly investigated, highlighting its high efficiency and effectiveness. This innovative approach represents a significant step forward in the production of BisAbs and offers a simpler, more accessible, and potentially scalable alternative to traditional genetic engineering techniques.Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug ConjugatesJournal of Medicinal Chemistry, 2024
- AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody–Drug Conjugate SynthesisOrganic Letters, 2024
- Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-GenerationACS Medicinal Chemistry Letters, 2023
- Scale-Up Synthesis of Site-Specific Antibody–Drug Conjugates Using AJICAP Second-Generation TechnologyOrganic Process Research & Development, 2023
- AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate ProductionBioconjugate Chemistry, 2023
- Tag‐Free Enzymatic Modification for Antibody−Drug Conjugate ProductionChemistrySelect, 2022
- Bispecific antibodies in oncologyNature Reviews Drug Discovery, 2022
- Lipoate-acid ligase a modification of native antibody: Synthesis and conjugation site analysisBioorganic & Medicinal Chemistry Letters, 2021
- Minireview: Addressing the retro-Michael instability of maleimide bioconjugatesDrug Discovery Today: Technologies, 2018
- Bridging Disulfides for Stable and Defined Antibody Drug ConjugatesBioconjugate Chemistry, 2014